Lipoprotein apheresis (LA) has long been a standard of care for patients with severe FH, but is invasive, expensive and time-consuming for patients and their caregivers. Newer drug therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may reduce the need for...
3. Ellis KL, Boffa MB, Sahebkar A, et al. The renaissance of lipoprotein(a): brave new world for preventive cardiology? Prog Lipid Res 2017; 68:57–82. 4. Boffa MB, Koschinsky ML. Proprotein convertase subtilisin/kexin type 9 ...
[1] Moustafa B, et al. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis[J]. J Stroke Cerebrovasc Dis, 2024, 33(4): 107633. [2] Zhou M, et al. Mortality, morbidi...
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, levels of lipoprotein (a). Efforts to prevent atherosclerotic heart ...
Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) LevelsLipoprotein (a) [Lp(a)] is a prevalent genetic risk factor for coronary artery disease [1] and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated significant Lp(a)-lowering effects [2, 3]....
11.Rivera F,et al. 1068-13-IMPACT OF PCSK-9 INHIBITORS ON LIPOPROTEIN(A): A META-ANALYSIS AND META-REGRESSION OF 47 RANDOMIZED CONTROLLED TRIALS. Presented at ACC.24. 12.Shatla I,et al.1492-217 / 217 - EARLY ADMINISTRATION OF PCSK-9 INHIBITOR FOR ACUTE CORONARY SYNDROME: A SYSTEMATIC...
cardiovascular incidents by administering PCSK9 inhibitors. PCSK9 inhibitors are a type of medication that lowers the levels of low-density lipoprotein cholesterol (LDL-C, also known as "bad" cholesterol) in the blood, which helps decrease the risk of heart disease and other cardiovascular ...
A. et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur. Heart J. 39, 2540–2545 (2018). CAS ...
Abstract ： PCSK9 inhibitors are a new type of drug used to reduce the level of low -density lipoprotein cholesterol. In recent years ， PCSK9 inhibitors have exhibited certain potential in the treatment of ischemic stroke ； however ， the research in ischemic stroke is still in its early ...
低密度脂蛋白(low-density lipoprotein, LDL)是一种脂蛋白颗粒,是运输胆固醇的载体。目前已有研究发现,升高的LDL胆固醇水平显著升高心梗和动脉粥样硬化性心血管疾病的风险[1]。因此,LDL胆固醇(LDL cholesterol, LDL-C)通常也被认为是一种“...